Background-Although renal insufficiency is a recognized risk factor for coronary artery disease, little is known about the epidemiology of lower-extremity peripheral arterial disease (PAD) in persons with renal insufficiency. Methods and Results-We examined the cross-sectional association of PAD, defined as an ankle-brachial index (ABI) Ͻ0.9, and renal insufficiency, defined as an estimated creatinine clearance (CRCL) Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 , among 2229 eligible participants in the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. An estimated 1.2Ϯ0.3 million persons Ն40 years old with CRCL Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 (24%) have PAD defined as an ABI Ͻ0.9 (versus 3.7% of persons with CRCL Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 ). The association of ABI Ͻ0.9 with renal insufficiency was independent of potential confounders such as age, diabetes, hypertension, coronary artery disease, stroke history, and hypercholesterolemia (OR 2.5, 95% CI 1.2 to 5.1, Pϭ0.011, referent category ABI 1.0 to 1.3). Conclusions-Clinicians should be aware of the remarkably high prevalence of PAD among patients with renal insufficiency. In the clinical setting, accurate identification of patients with renal insufficiency combined with routine ABI measurement in this group would greatly enhance efforts to detect subclinical PAD. (Circulation. 2004;109:320-323.)
I t is increasingly accepted that mild to moderate chronic renal insufficiency is a risk factor for cardiovascular disease. [1] [2] [3] [4] [5] However, most studies of cardiovascular disease in patients with chronic renal insufficiency have not examined lower-extremity peripheral arterial disease (PAD), and disease prevalence has only been described in a few select groups of patients with renal insufficiency. 6 -8 Because PAD is highly prevalent among dialysis patients, 9 as evidenced by the exceedingly high amputation rates in this group, 10 we hypothesize that there is also a high prevalence of PAD among the much larger number of persons with chronic renal insufficiency. We used ankle-brachial index (ABI) measurements from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000 to test this hypothesis.
Methods

Data Sources
Since the early 1960s, the National Center for Health Statistics has conducted a series of cross-sectional national surveys of the noninstitutionalized civilian population. In each survey, the population was sampled with a complex, stratified, multistage probability cluster sampling design to provide data that are representative of the overall United States population. Beginning in 1999, NHANES became a continuous survey, and NHANES 1999 to 2000 refers to the first 2 years of data for the now ongoing NHANES. As for the prior NHANES, NHANES 1999 to 2000 involved collection of interview, examination, and laboratory data. However, unlike prior surveys, the present survey included a detailed lower-extremity examination that involved ABI measurement, a noninvasive measure of lower-extremity atherosclerosis. It is thus possible to use NHANES 1999 to 2000 data to estimate the prevalence and correlates of PAD as indicated by a low ABI. More detailed information on survey design and procedures is available at http://www.cdc.gov/nchs/about/major/ nhanes/NHANESIII_Reference_ Manuals.htm.
ABI Measurements
Briefly, study participants Ն40 years old were invited to undergo lower-extremity examination. Persons with bilateral amputations or weighing more than 400 pounds were excluded. Supine systolic pressure was measured in 1 arm (brachial artery) and both ankles (posterior tibial arteries). The ABI was calculated by dividing the mean systolic blood pressure in the arm by the mean systolic blood pressure in the respective ankle. For the purposes of this analysis, the lowest ABI obtained for either leg was taken as the ABI measurement for that patient. Details of the ABI measurement procedure in NHANES 1999 to 2000 are available at http://www.cdc.gov/nchs/data/nhanes/frequency/lexabdoc.pdf.
Estimation of Creatinine Clearance
We used the Cockroft-Gault formula standardized to body surface area 11 to estimate creatinine clearance (CRCL). 12 For the purposes of this analysis, subjects were considered to have renal insufficiency if their estimated CRCL was Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 . All analyses compare this group with the reference group of persons with estimated CRCL Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 .
Covariates
Self-reported race was defined as non-Hispanic black versus all other. Determination of comorbid conditions (diabetes, insulin use, diabetic retinopathy, hypertension, coronary artery disease, stroke history, and smoking history) was based on patient interview responses. In addition, body mass index (BMI), the average of 4 measurements of systolic and diastolic blood pressure, glycosylated hemoglobin, and total cholesterol measurements were included in multivariable analysis.
Statistical Analysis
Sampling weights are provided with NHANES 1999 to 2000 data. These take into account the unequal probabilities of selection that result from the sample design, from nonresponse, and from planned oversampling of certain subgroups. Standard errors were calculated by the recommended jackknife method (http://www.cdc.gov/nchs/ data/nhanes/guidelines1.pdf) with SAS-callable SUDAAN version 8 software (Research Triangle Park). Differences in continuous variables between renal function categories were compared with a t test, and differences in categorical variables were measured with a 2 test. We developed a categorical variable for ABI that adhered to conventional ABI cutoff points (ie, ABI Ͻ0.9, 0.9 to 0.99, 1.0 to 1.3, and Ͼ1.3). PAD is defined as an ABI Ͻ0.9, and values between 1.0 and 1.3 are considered normal. 13 An ABI of 1.0 to 1.3 served as the referent category for all logistic regression analyses. We measured the association of the categorical ABI variable with renal insufficiency using univariate logistic regression analysis for which the outcome was estimated CRCL Ͻ60 versus Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 . We then developed multivariate logistic regression models to adjust sequentially for confounders including demographic (age, gender, and race) and clinical characteristics (diabetes, insulin use, retinopathy, coronary artery disease, stroke history, cholesterol, glycosylated hemoglobin, smoking history, BMI, hypertension history, and blood pressure measurements).
Results
ABI was recorded for at least 1 leg in 2381 (83%) of the 2875 lower-extremity examination participants. Serum creatinine was measured in 2233 of these participants. Four participants were excluded because they were missing weight data, and we were therefore unable to estimate CRCL. The study sample thus consisted of 2229 persons with ABI and CRCL data. Among these, 211 had an estimated CRCL Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 (a projected 5.8Ϯ0.7% of the noninstitutionalized civilian population more than 40 years old, or 5.0Ϯ0.6 million persons). Table 1 describes the characteristics of the study sample extrapolated to the US population. A substantially higher percentage of persons with renal insufficiency were in the low ABI categories (Ͻ0.9 and 0.9 to 0.99) compared with those with CRCL Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 . However, those with renal insufficiency were on average older; had a higher prevalence of diabetes, coronary artery disease, stroke, and hypertension; had higher mean glycosy- lated hemoglobin and systolic pressure; and had lower BMI and diastolic blood pressure. There were no statistically significant differences between persons with and without renal insufficiency in either total cholesterol measurements or smoking history. Among persons with renal insufficiency, the prevalence of ABI Ͻ0.9 was high both among those with (29Ϯ9%) and without (21Ϯ5%) self-reported coronary artery disease. On the basis of this analysis, the population prevalence of PAD (as defined by an ABI Ͻ0.9) among persons Ն40 years old with an estimated CRCL Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 is estimated to be 1.2Ϯ0.3 million. Table 2 shows the results of both univariate and multivariate logistic regression analyses. Univariate logistic regression analysis shows that compared with their counterparts with CRCL Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 , persons with renal insufficiency were more than 9-fold more likely to have an ABI Ͻ0.9 (versus an ABI of 1 to 1.3). We developed 2 multivariable models to adjust sequentially for demographic characteristics and comorbid conditions that might confound the association between renal insufficiency and ABI. After adjustment for age, gender, and race, renal insufficiency remained strongly associated with an ABI Ͻ0.9 (OR 3.0, 95% CI 1.7 to 5.3, PϽ0.001). This association persisted after further adjustment for comorbid conditions including diabetes, coronary artery disease, and history of stroke; measures of diabetes severity (glycosylated hemoglobin, self-reported retinopathy, and insulin use); history of diagnosed hypertension; and measured blood pressure, total cholesterol, BMI, and smoking history (ABI Ͻ0.9; OR 2.5, 95% CI 1.2 to 5.1, Pϭ0.011, referent category ABI 1.0 to 1.3).
Discussion
The present study demonstrates a remarkably high prevalence of PAD (defined as an ABI Ͻ0.9) among a representative sample of the US population Ն40 years old with renal insufficiency. On the basis of these data, an estimated 1.2Ϯ0.3 million persons (24%) Ն40 years old with a CRCL Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 have PAD. Even after adjustment for important confounders such as age, diabetes, diabetes severity, and coronary artery and cerebrovascular disease, persons with renal insufficiency are still more than twice as likely to have an ABI Ͻ0.9 as persons with a CRCL Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 .
The high unadjusted association of renal insufficiency with low ABI reflects, to a large extent, the older age of the renal insufficiency group. A high prevalence in this group of other established cardiovascular risk factors such as diabetes and hypertension, in addition to a high prevalence of existing coronary artery and cerebrovascular disease, also contributes to the high unadjusted association of renal insufficiency with low ABI. Several traditional cardiovascular risk factors, such as cholesterol and smoking, are no more prevalent among persons with renal insufficiency than among those with normal renal function and thus do not appear to explain the cross-sectional association seen here between ABI and renal insufficiency.
There are several possible explanations for the high adjusted association of renal insufficiency with low ABI. One possibility is that renal insufficiency may be a marker for more generalized atherosclerosis. In support of this, the presence of baseline cardiovascular disease is independently associated with progression to end-stage renal disease among patients with chronic kidney disease. 14 Alternatively, there may be a causal association between renal insufficiency and progression of lower-extremity atherosclerosis. Potential pathophysiological mechanisms by which decreased CRCL itself might predispose to PAD include altered calciumphosphorus, homocysteine, and lipoprotein(a) metabolism and alterations in inflammatory and coagulation pathways. 9 Accurate diagnosis of PAD is important. Low ABI is associated with an increased risk of stroke, myocardial infarction, and cardiovascular death, and PAD is known to affect lower-extremity function and quality of life. 15 Several specific interventions, such as exercise training 16 and statin therapy, 17 are effective in reducing the functional limitation associated with PAD. Unfortunately, in part owing to the lack of specific PAD symptomatology, clinician awareness of PAD in the primary care setting is notoriously low, 15, 18 which translates into missed opportunities to prescribe specific therapy for PAD and to implement general cardiovascular risk reduction measures for this high-risk group. 18 Relative to methods for detecting other forms of cardiovascular disease (eg, cardiac stress testing), ABI measurement is a simple, noninvasive procedure that can be performed easily in the outpatient setting. 15 Routine ABI measurement could be used to identify patients with subclinical PAD who might benefit from educational and therapeutic interventions for PAD. Early identification of PAD before progression to advanced ischemia may be particularly important in patients with renal insufficiency, given data showing that patients with renal insufficiency who undergo lowerextremity bypass are more likely than those with normal renal function to present with gangrene and ischemic ulceration at the time of surgery and to experience postoperative death and cardiovascular complications. 19 In addition, because of the well-documented association of low ABI with cardiovascular mortality, ABI measurement could also help to target patients at highest risk for cardiovascular death as candidates for secondary prevention efforts. The present results show that self-reported history of coronary artery disease is an insensitive predictor of low ABI in patients with renal insufficiency. Thus, measurement of ABI in patients with renal insufficiency could contribute valuable information on cardiac risk beyond what is supplied by the medical history alone. NHANES provides nationally representative data and overcomes many problems of sampling bias, but the present findings must be interpreted in the context of the study design. Specifically, it is unclear from these cross-sectional data whether renal insufficiency is a true causal "risk factor" for the development of PAD. Although renal insufficiency does appear to be associated with the future development of claudication, 20 further studies are needed to measure the association of baseline renal insufficiency with progression of PAD and future PAD events. A second concern is that the present analysis may underestimate the prevalence of PAD in persons with renal insufficiency because of the high prevalence of vascular calcification in this group, leading to falsely elevated ABIs. In this situation, a toe brachial index may be a more accurate screening test for PAD. We are unable to overcome this limitation because toe pressures were not measured in NHANES 1999 to 2000.
Conclusions
PAD is remarkably common in persons with renal insufficiency, and there is an independent cross-sectional association between PAD and renal insufficiency. In the primary care setting, the combination of accurate diagnosis of renal insufficiency (either via measurement or estimation of CRCL or via estimation of glomerular filtration rate) and routine ABI measurement in this group would facilitate more efficient identification of patients with subclinical PAD, a group most likely to benefit from PAD-specific educational interventions and therapy and also from more general cardiovascular risk-reduction efforts.
